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Abstract
Background—Individual variation in circulating insulin-like growth factor-I (IGF1) and its
major binding protein, insulin-like growth factor binding protein-3 (IGFBP3) have been
etiologically linked to several chronic diseases, including some cancers. Factors associated with
variation in circulating levels of these peptide hormones remain unclear.
Methods—Multiple linear regression models were used to determine the extent to which socio-
demographic characteristics, lifestyle factors, personal and family history of chronic disease, and
common genetic variants, the (CA)n repeat polymorphism in the IGF1 promoter and the IGFBP3
-202 A/C polymorphism (rs2854744) predict variation in IGF1 or IGFBP3 serum levels in 33
otherwise healthy African American and 37 white males recruited from Durham Veterans
Administration Medical Center.
Results—Predictors of serum IGF1, IGFBP3 and the IGF1:IGFBP3 molar ratio varied by race.
In African Americans, 17% and 28% of the variation in serum IGF1 and the IGF1:IGFBP3 molar
ratio, respectively, was explained by cigarette smoking and carrying the IGF1 (CA)19 repeat allele,
respectively. Not carrying at least one IGF1 (CA)19 repeat allele and a high BMI explained 8%
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and 14%, respectively, of the variation IGFBP3 levels. These factors did not predict variation of
these peptides in whites.
Conclusion—If successfully replicated in larger studies, these findings add to recent evidence
suggesting known genetic and lifestyle chronic disease risk factors influence IGF1 and IGFBP3
circulating levels differently in African Americans and whites.
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Introduction
IGF1 is a potent broad-spectrum mitogenic growth factor with antiapoptotic properties.
Elevated circulating concentrations of IGF1 have been etiologically linked to several chronic
diseases, including type-2 diabetes,1 cardiovascular diseases,2, 3 and cancers of the breast,4–
6 colon,7, 8 and prostate.6, 9–18 Circulating IGF1 levels are modulated by the formation of
the ternary complex that binds to IGFBP3 and/or IGFBP5 and an acid labile subunit (ALS)
too large to pass through the endothelial wall.6, 19 Independently of regulating the
availability of IGF1 in circulation, IGFBP3 also induces apoptosis.20 Lower circulating
concentrations of IGFBP3 have also been linked to increased risk of several malignancies.6,
9, 11, 13, 17, 21–23
For reasons that are still poorly understood, there is considerable inter-individual variation in
serum concentrations of both IGF1 and IGFBP3. Whereas age-related declines in IGF1 and
IGFBP3 serum levels have been repeatedly demonstrated in men and women,24–27 data on
the utility of demographic and lifestyle factors such as cigarette smoking, sex,24, 26, 28, 29
race,30–33 and body mass index (BMI), to predict variation in these peptides are
inconsistent. In addition, although common nonsynonymous genetic variants in IGF1 and
IGFBP3 have been evaluated in relation to chronic disease risk in many case-control studies
because of their association with circulating protein products of these genes, the capacity of
these variants to predict circulating levels also remains unclear.27, 34–36 The availability of
both genetic variant and lifestyle data in otherwise healthy African American and white men
provided the impetus to evaluate the extent to which together these factors predict IGF1 and
IGFBP3 serum concentrations in healthy men.
Methods
Study Participants
Participants included in these analyses served as healthy controls for a hospital-based, case-
control study of prostate cancer conducted at the Durham Veterans Administration Medical
Center (DVAMC). Methods of participant accrual and data collection have been detailed
elsewhere. 37, 38 Briefly, as part of a hospital-based, case-control study, 181 consecutive
hospital controls aged 40 to 75 years were identified and matched to cases by race and age,
between January, 1999, and July, 2001, at the DVAMC, North Carolina. Of the 181 controls
identified, 96 were enrolled, 2 withdrew, and 2 were lost between identification and
interview, a response rate of 53%. We further excluded 26 men for whom genotype or other
covariate data were unavailable such that 70 participants were available for these analyses,
33 of them African American.
Data Collection
On scheduled visits to the DVAMC, a trained nurse conducted in-person interviews using a
standardized questionnaire to obtain data on socio-demographic and lifestyle factors, as well
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as family and personal history of several chronic diseases, including prostate cancer, other
cancers, and diabetes. Following the interview, 30mls of peripheral blood were collected in
10mls EDTA-treated tubes. Serum and buffy coat were isolated within 2hours of collection
and stored in a −70°C freezer. PureGene system reagents (Gentra, Minneapolis, MN) were
used to extract and re-suspend genomic DNA according to manufacturer’s protocol.
Genotyping
Detailed methods for ascertaining polymorphic variants also have been previously
described. To determine the repeat length of the IGF1 (CA)n microsatellite, located 1kb
upstream of the gene’s transcription start site, PCR was performed using previously
published unlabelled primers obtained from Integrated DNA Technologies (Coralville,
Iowa). The forward and reverse primers used were 5’-GCT AGC CAG CTG GTG TTA
TT-3’ and 5’-ACC ACT CTG GGA GAA GGG TA-3’, respectively. The IGFBP3 single
nucleotide polymorphism (-202 (A/C) (rs2854744) was analyzed according to Deal et al. 34
The forward and reverse primers used were 5’-CCA CGA GGT ACA CAC GAA TG-3’ and
5’-AGC CGC AGT GCT CGC ATC TGG-3’, respectively.
Serum measurement of IGF1 and IGFBP3
We measured IGF1 and IGFBP3 concentrations at the time of data collection. Measurements
were according to manufacturer’s protocol, in duplicate using commercially available
enzyme-linked immunosorbent assay (ELISA) kits (Diagnostic Systems Laboratories,
Webster, TX). Each assay batch included positive controls and masked samples derived
from pooled serum specimens. If the two measurements were widely divergent (an
infrequent occurrence), assays were repeated up to two additional times. The average of two
measurements for each analyte was used for data analysis. The sensitivities of the assay used
were as follows: IGF1=0.03ng/ml and IGFBP3=0.04ng/ml. In addition to quantifying IGF1
and IGFBP3 concentrations, we also estimated the molar ratio of IGF1/IGFBP3 as the
quantity (IGF1 in ng/ml*0.130)/IGFBP3ng/ml*0.036) where the constants are the molecular
weights of the respective polypeptide. The molar ratio is often used as a surrogate for the
more relevant unbound IGF1. 24, 31
Statistical analyses
Age-adjusted means and standard deviations for IGF1, IGFBP3 and the IGF1:IGFBP3 molar
ratio, were computed for the overall sample and in the presence and absence of each
predictor for African Americans and whites together as well as separately by race. Predictors
were dichotomized as follows: age (<60 years v. older ≥60 years); education (graduated
from high school v. not graduated from high school); smoking (100 cigarettes in a lifetime v.
never smoked 100 cigarettes in a lifetime); diabetic v. not diabetic; normal BMI
(BMI<25kg/m2) v. overweight (BMI=25-<30kg/m2) v. obese (BMI≥30kg/m2); family
history of prostate cancer in father or brother v. none; homozygote and heterozygote carriers
v. noncarrier of the IGF1 (CA)19 repeat allele; homozygote and heterozygote carriers v.
noncarrier of the IGFBP3 −202bp A-allele. Multiple regression models using PROC REG in
SAS (Cary, NC) were used to identify factors independently associated with IGF1 and
IGFBP3 levels. Using backward selection strategies, beta coefficients and partial r2 for each
factor in the final model were also computed to determine the proportion of variation
contributed by each factor. Although age did not independently predict decrease in total
IGF1 or IGFBP3 concentration, it was retained in all models since it is a known determinant
of these peptides. Statistical analyses were conducted using SAS version 9.3 (SAS, Cary,
NC, USA).
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The distribution and age-adjusted means and 95% confidence intervals for serum IGF1,
IGFBP3 and IGF1:IGFBP3 molar ratios of 33 African American and 37 white men are
presented in Table 1. Among all participants, serum levels of IGF1, IGFBP3 and
IGF1:IGFBP3 molar ratio did not vary significantly by diabetes, body mass index, family
history of prostate cancer or carrying the A/C at −202bp of the IGFBP3 genotypes.
However, African-American noncarriers of the IGF1 (CA) 19 repeat had lower IGF1 levels
(117; 95%CI=94–140ng/ml) and lower IGF1:IGFBP3 molar ratio (0.21; 95%CI=0.17–0.25)
compared to whites. Also, cigarette smoking African Americans had somewhat lower
IGF1:IGFBP3 molar ratio and IGF1 levels compared to white smokers (IGF1 mean=114ng/
ml; 95%CI=97–130 for African Americans versus mean=131ng/ml; 95%CI=109–153 for
whites; IGFBP1:IGFBP3 molar ratio 0.22 and 0.27 for African Americans and white men,
respectively). African-American men with a high BMI had lower levels of IGF1 and
IGF1:IGFBP3 molar ratio compared to whites.
Similar to previous reports39, 40, in race-stratified analyses multivariable regression models
fit to identify significant predictors of serum concentrations of IGF1, and IGF1/IGFBP-3
molar ratio (Table 2), we found that age, circulating IGF1 and IGFBP3 were inversely
related, predicting most of the variation in serum IGF1 and IGFBP3. In contrast, no other
factors were significant predictors of circulating IGF1 or IGFBP3 levels in white men.
However, in African-American men, the two independent predictors of serum IGF1 levels
were; a history of cigarette smoking and carrying the IGF1 (CA)19 repeat allele. These two
factors explained 17% of the individual variation in IGF1 and 28% of the variation in
IGF1:IGFBP3 molar ratio, whereas, a large BMI and being a noncarrier of the IGF1 (CA)19
repeat explained 22% of the variation in circulating IGFBP3. Factors previously reported to
predict IGF1 and IGFBP3, including a high fat diet, alcohol use, diabetes, carrying the
IGFBP3 –202 C-allele, and a large waist circumference, did not independently predict
serum IGF1 or IGFBP3 in African Americans or whites
Discussion
In this study, we found that the effect of lifestyle factors, including cigarette smoking and a
large BMI as well as carrying at least one IGF1 (CA)19 repeat allele predicted serum IGF1
and IGFBP3 in African Americans but not whites, explaining 28% of the variation in
IGF1:IGFBP3 molar ratio; 17% of the variation in serum IGF1 and 22% of the variation in
serum IGFBP3. These findings contrast with those of other studies where no racial
differences in the effect of genetic or lifestyle factors were found. 39–41 Although IGF1 and
IGFBP3 proteins have been evaluated extensively in different race/ethnic groups, to our
knowledge, this is the first study to demonstrate the utility of this common genetic variant
together with lifestyle factors to predict serum IGF1 and IGFBP3 in otherwise healthy
African- American men, suggesting that race/ethnicity-dependent mechanisms are
important. If confirmed, these findings may explain, in part, inconsistent findings among
studies evaluating associations between established risk factors and chronic disease
endpoints where race/ethnicity is data are not taken into account.
The finding that carrying at least one copy of the IGF1 (CA)19 dinucleotide repeat allele
predicted IGF1 and IGFBP3 levels in African Americans, but not in whites contrasts with at
least three of the five studies that have evaluated the association between carrying the
IGF1(CA)19 allele, and IGF1 or IGFBP3 levels24, 31, 35, 36 where lower levels of IGF1
were found among predominantly white individuals carrying this common genetic variant.
In Japanese27 and British42 studies, no association between carrying the IGF1 (CA)19 repeat
allele and IGF1 levels was found, although increased IGFBP3 levels were noted by others.27
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These studies had few or no African Americans. In a large American multiethnic study, no
race/ethnic differences in the relationship between carrying the IGFBP3 -202A/C and serum
IGFBP3 or IGF1 were noted.40
Our findings that African-American men with a history of cigarette smoking had lower IGF1
levels and a lower IGF1:IGFBP3 molar ratio are consistent with those of some previous
studies,43, 44 although not all studies have confirmed this association.26, 29, 45, 46 The
association between a higher BMI and higher IGFBP3 levels have also been reported by
some30, 42, 44 although others did not find this association.24,47 While the mechanisms
underlying racial/ethnic differential effects of common environmental stressors such as a
large BMI and cigarette smoking are still under investigation, if confirmed by other studies,
our findings will contribute to our understanding of chronic disease risk involving IGF-
signaling in African Americans.
A limitation of the analyses was that while our sample size was adequate to assess the
independent effects of the factors under investigation, it was inadequate to evaluate the
interaction between genetic factors and demographic and lifestyle factors on serum IGFBP3
or IGF1. However, a larger more recently published study reported no interaction effect
between the IGFBP3 -202A/C variant and lifestyle factors.40 Another limitation is the low
(53%) response rate, potentially raising concerns about the generalizability of findings to the
general population. However, the main reason for non-response was failure to contact
following identification by clinic registries; a reason unlikely to be related to serum IGFI or
IGFBP3 or factors assessed in our analyses.
In summary, commonly identified risk factors for chronic diseases, including a history of
cigarette smoking, a large BMI and carrying at least one IGF1 (CA)19 repeat allele predicted
variation in serum IGF1 and IGFBP3 levels in African-American men but not white men.
These findings suggest that while variations in serum IGFs are clearly regulated by
endogenous complex physiologic systems, some lifestyle and genetic variants appear to
operate differently depending on race/ethnicity. If confirmed in larger studies, our
observations will contribute to a more detailed understanding of ethnicity/race-specific
insulin-like growth factor signaling pathway which should guide public health and
therapeutic interventions.
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